This test is most useful if any of these apply to you.
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. It can cause palpitations or go unnoticed, sometimes until a stroke occurs. Inherited differences contribute to its development, and the chromosome 4q25 region has one of the strongest and most consistently replicated genetic associations with AF.
This test reads one common variant in that region. Its association with AF is well established, but using this single result to choose screening or treatment remains exploratory. It adds information about inherited susceptibility without providing a diagnosis or a reliable estimate of your personal lifetime risk.
The result identifies the DNA letters at rs2200733. The label 4q25 describes its location on the long arm of chromosome 4. The two versions are C and T, with T associated with higher AF risk. You inherit one copy from each parent, so the result is CC, CT, or TT.
The variant sits between genes and doesn't alter a protein's sequence. Nearby PITX2 helps control heart development and electrical function. Mouse experiments link Pitx2c to formation of the muscle surrounding the pulmonary veins. Electrical activity from that muscle commonly triggers AF.
The biological explanation is still being worked out. A 2026 study found that the rs2200733 risk version was associated with increased activity of the PITX2C form of the gene in human atrial tissue. Experiments on isolated human heart cells also found differences in calcium handling and electrical activity. These findings don't support a simple account in which the T version always turns PITX2 down.
In a separate study of people undergoing AF ablation, carriers had more uneven electrical conduction when their atria were mapped. These observations help explain why the region interests researchers, but they don't establish what happens in every carrier's heart.
The original discovery study found about 1.7 times the odds of AF per T copy in European samples. A later meta-analysis pooled seven studies and about 83,000 people. After adjustment for other risk factors, carriers in the five European studies had about 1.9 times the odds of AF compared with non-carriers, while the two Chinese studies pooled to about 1.5. The individual studies disagreed considerably. An increase in odds isn't the same as an increase in your absolute probability of developing AF.
Estimates vary with the population and study design. One meta-analysis found about 1.4 times the odds in community cohorts, compared with about 1.8 in case-control studies that recruited people with and without AF. These differences are one reason a single published figure shouldn't be turned into a personal risk forecast.
Age, blood pressure, weight, diabetes, heart disease, and other genetic variants also contribute. The T version can be present in someone who never develops AF, while someone with CC can still develop it. The result doesn't show whether an irregular rhythm is happening now.
Some studies found a stronger association in AF occurring without recognized heart disease or other usual risk factors. Older papers often called this lone AF, although definitions varied and the term is now discouraged.
In a Chinese Han study, the T version was associated with about 2.4 times the odds of lone AF, compared with about 1.6 times the odds of other AF. A Danish study also found an association in people whose AF began before age 40. These findings support a genetic contribution to early AF; they don't show that screening healthy younger adults for this single variant improves outcomes.
Rare variants in genes such as SCN5A and KCNQ1 can contribute to inherited rhythm disorders. In a small study of 11 families, researchers examined rs2200733 together with another common 4q25 variant and rare variants in heart-related genes. The combination was associated with which relatives had AF, suggesting that common variants can modify the effects of rarer ones. This test doesn't examine those rare variants.
AF can allow blood clots to form in the heart and travel to the brain. An ischemic stroke occurs when blood flow to the brain is blocked. In European studies, each rs2200733 T copy was associated with about a quarter higher odds of ischemic stroke. The association was stronger for strokes attributed to a clot from the heart, with about half higher odds.
A Chinese Han study did not detect an association with ischemic stroke. Undetected AF is a plausible explanation for part of the European stroke association, but these studies don't establish that testing this variant and acting on the result prevents strokes.
Atrial flutter is another rhythm disorder. Its typical form involves a fast electrical circuit in the right atrium. Italian and US studies linked rs2200733 to flutter as well as AF. The US study did not detect a difference in subsequent AF after typical flutter ablation between carriers and non-carriers.
Several observational studies have linked rs2200733 to recurrence after AF treatment. Catheter ablation treats tissue involved in abnormal electrical signals. Electrical cardioversion uses a timed shock to restore a normal rhythm.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 991 adults undergoing AF ablation at three centers | CT or TT compared with CC | Carriers had about a 30 percent higher rate of recurrent atrial rhythm disturbances during one-year follow-up. |
| 311 adults undergoing 378 AF ablation procedures at one center | CT and TT compared with CC | Estimated time free of recurrent atrial rhythm disturbances was about a fifth shorter with CT and about two fifths shorter with TT. |
| 162 adults whose normal rhythm was restored by cardioversion | TT compared with CC | The reported median time to AF recurrence was 7 days with TT and 64 days with CC. |
The ablation outcomes included AF and other atrial rhythm disturbances. Results have not been consistent across populations: a Korean study found no association between these common AF variants and ablation success. These studies have not established that choosing a procedure, drug, or follow-up schedule based on rs2200733 improves your outcome.
The frequency of T and its estimated effect differ across ancestry groups. A result that is common in one population may be much less common in another, and an estimate from a European study may not transfer directly to your background.
The 4q25 region contains several separate risk signals. In one study combining three signals, the highest-risk combination was associated with about six times the AF risk of the most common combination. That comparison involved several DNA positions, so it cannot be applied to a TT result from this test.
Scores combining variants across the genome can provide more information than a single position. In a study of adults with symptoms or clinical risk factors, those in the highest fifth of a 12-variant score had about three times the odds of newly detected AF compared with the lowest fifth. AF was detected with ECGs or ambulatory monitoring.
Larger genetic scores have added information to clinical risk factors and NT-proBNP in cardiovascular disease cohorts. NT-proBNP is a blood marker of strain on the heart. A separate research model based on blood proteins predicted AF better than the genetic model it was compared with, and adding genetics did not improve its performance. Neither result validates this single variant as a stand-alone screening tool.
Your inherited genotype is permanent, so routine repeat testing has no role. Its value is as background information alongside your family history and heart health. Blood pressure, symptoms, and heart rhythm can change over time; the timing of those checks follows your clinical risk, because this variant alone doesn't establish a monitoring schedule.
4q25 AF Risk Genotype (rs2200733) is best interpreted alongside these tests.
4q25 AF Risk Genotype (rs2200733) is included in these pre-built panels.
Understand part of your inherited tendency toward an irregular heart rhythm, even before symptoms appear.